PD-1/PD-L1-IN-65 

PD-1/PD-L1-IN-65 is a PD-1/PD-L1 checkpoint inhibitor, with an EC₅₀ of 6.06 μM for blocking the PD-1/PD-L1 interaction and a K_d of 1.43 μM for PD-L1. PD-1/PD-L1-IN-65 upregulates pro-inflammatory cytokines IFN-γ, IL-1α, IL-1β and the cytolytic protein perforin, and reverses T cell exhaustion. PD-1/PD-L1-IN-65 enhances T cell-mediated cancer cell lysis. PD-1/PD-L1-IN-65 can be used in the research of breast cancer^[1].

PD-1/PD-L1-IN-65 (Compound 17h) functionally blocks the interaction between PD-1 and PD-L1 in competitive ELISA assays, with an EC₅₀ value of 6.06 μM^[1].
PD-1/PD-L1-IN-65 (8 μM; 0.0327-8 μM) effectively restores T cell signaling in cell-based PD-1/PD-L1 blockade assays, with an EC₅₀ of 215 nM^[1].
PD-1/PD-L1-IN-65 (10 μM) reverses PD-L1-mediated immunosuppression in the MDA-MB-231/activated PBMC co-culture system by upregulating IFN-γ, IL-1α, IL-1β, and perforin^[1].
PD-1/PD-L1-IN-65 (5-10 μM) enhances T cell-mediated lysis of MDA-MB-231 cells without intrinsic cytotoxicity, confirming its selective immunomodulatory activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

560.59

C₃₀H₂₃F₃N₄O₂S

CC1=C(SC(C2=CC=C(C(C#N)=C2)OCC(C)C)=N1)C(NC3=C(C(C4=CC=CC(C(F)(F)F)=C4)=CC=C3)C#N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Karamtoth S, et al. New thiazole-biaryls as small molecule immunomodulators (SMIs) targeting PD-1/PD-L1 axis. Bioorg Med Chem Lett. 2026 Sep;138:130687.